[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620715":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":47,"collaborators":20,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CLS-015 infusions after CAR-T infusion","EXPERIMENTAL","CLS-015 infusions will be done on Days 0,3,6,10 and 15 after CAR-T infusion",[13],"Drug: rhDNase I",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","rhDNase I","CLS-015 IV infusions after CAR-T infusion done on Days 0,3,6,10 and 15 after CAR-T infusion",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Ron Ram, Prof.","Sourasky Medical Center","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","972-3-6973782","ronr@tlvmc.gov.il",[32],{"facility":24,"status":33,"city":34,"state":20,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Tel Aviv","6423906","Israel","IL",{"type":39,"coordinates":40},"Point",[41,42],34.78057,32.08088,{"lat":42,"lon":41},[45],{"name":23,"role":28,"phone":46,"phoneExt":20,"email":30},"97236974629",{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100620715","phase-1-investigator-initiated-study-to-assess-the-safety-of-combination-of-cls-015-with-anti-cd-19-car-t-cells-in-patients-with-stableprogressive-large-b-cell-lymphoma-at-lymphodepletion-100620715",false,"NCT07361224","Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable\u002FProgressive Large B Cell Lymphoma at Lymphodepletion.","CLS-015-TAMSC-LBCL-PR An Exploratory, Investigator Initiated Study to Assess the Safety of Combination of CLS-015 (DFF) With Anti-CD-19 CAR-T Cells in Patients With Stable\u002F Progressive Large B Cell Lymphoma at Lymphodepletion.","Inclusion Criteria:\n\n* Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.\n* Large B-Cell lymphoma treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)\n* Stable Disease or Progressive Disease confirmed by PET-CT on the day of lymphodepletion\n* Capable of giving signed informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria:\n\n* Hypersensitivity to CLS-015\n* Evidence of any clinically significant condition, disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.\n* Active infection requiring antibiotics\n* Females only: Pregnant or breastfeeding","ALL","18 Years",{"count":59,"type":60},12,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.",[66],"Large B-Cell Lymphoma (LBCL)",[68],"Large B-Cell lymphoma","2026-04-27",{"date":71,"type":72},"2026-05-01","ACTUAL",{"date":74,"type":60},"2026-05",{"date":76,"type":60},"2028-02",{"name":5,"class":6},1]